Observational studyEuropean journal of clinical pharmacology2025
Evaluating the risk of atrial fibrillation in patients with chronic recurrent pericarditis prescribed colchicine: Observations using TriNetX global federated research network.
Observational study in European journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammation-Mediated Mechanisms of Arrhythmias After Acute Myocardial Infarction.Reviews in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic pericarditis is associated with significant cardiovascular morbidity, including atrial fibrillation (AF), heart failure (HF), and stroke. Colchicine is widely used in pericarditis management for its anti-inflammatory effects, but its impact on arrhythmias and other cardiovascular outcomes remains uncertain.
methodsWe conducted a retrospective observational cohort study using the TriNetX global federated research network to assess the association between colchicine use and cardiovascular outcomes in in-patients with chronic pericarditis. Patients diagnosed with chronic adhesive and constrictive pericarditis with or without colchicine use between 2010 and 2024 were included. Propensity score matching (PSM) (1:1) was used to balance baseline characteristics. The primary outcome was 1-year incidence of AF. Secondary outcomes included all-cause mortality, ischemic stroke, acute myocardial infarction (AMI), acute HF, cardiac arrest, ventricular arrhythmias, and a composite cardiovascular outcome.
resultsOf 8,120 patients hospitalized with chronic pericarditis, 1,064 received colchicine. 1,061 patients were matched in each group after PSM. The 1-year incidence of AF was similar between colchicine users and non-users (HR: 0.90, 95% CI: 0.76–1.06) after PSM. Colchicine use was associated with significantly lower risk of all-cause mortality (HR: 0.67, 95% CI: 0.54–0.84) and ischemic stroke (HR: 0.45, 95% CI: 0.29–0.67) after PSM. No significant differences were observed for AMI, cardiac arrest, HF, or ventricular arrhythmias.
conclusionIn this real-world cohort of patients with chronic pericarditis, colchicine did not increase the risk of AF. Colchicine was linked to significantly lower risks of all-cause mortality and ischemic stroke in hospitalized chronic pericarditis patients, suggesting potential systemic cardiovascular benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.